US Selumetinib Registry
The purpose of this study is to understand treatment patterns and assess long-term effectiveness and safety outcomes associated with selumetinib treatment as well as to explore clinical and non-clinical factors affecting those outcomes in patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs) who started selumetinib between the ages of 2 to 18 years inclusive, and initiated selumetinib treatment on or after 10 April 2020 in a real-world setting.
Neurofibromatosis Type 1|Plexiform Neurofibromas
Number of Participants with Improvement in Clinically Significant Plexiform Neurofibromas (PNs) as Assessed by the Treating Physician, Up to Month 60|Number of Participants with Improvement in Disease Status as Assessed by the Treating Physician, Up to Month 60|Number of Participants with Improvement in Neurofibromatosis type 1 (NF1) Skeletal Manifestations, Skeletal manifestations may include changes in the angle of spine curvature., Up to Month 60|Number of Participants with Treatment Emergent Medical Events of Interest (MEOI), Up to Month 60
Change From Baseline in the Numerical Rating Scale (NRS-11) Score at Month 60, Baseline, Month 60|Change From Baseline in the Pain Interference Index (PII) Score at Month 60, Baseline, Month 60|Change From Baseline in the Patient Global Impression of Change (GIC) Scale at Month 60, Baseline, Month 60|Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) at Month 60, Baseline, Month 60
This is a US observational registry of pediatric NF1 PN participants treated with selumetinib.